Clinical Trial Update: Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating a combination of trastuzumab, HS627, pertuzumab, and docetaxel for breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• HS627 (HS627)
• Pertuzumab (pertuzumab)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: BioRay Pharmaceutical Co., Ltd. | Conditions: Breast Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING